Trial of JYB1904 in Patients With Allergic Asthma

Sponsor
Jemincare
Study ID
NCT06438757
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • JYB1904 — DRUG
    Participants will receive JYB1904 every 8 weeks for 24 weeks.
  • Omalizumab — DRUG
    Participants will receive Omalizumab every 2/4 weeks for 24 weeks.

Study Details

This phase IIa trial is meant to evaluate the pharmacokinetics, pharmacodynamics and safety of JYB1904 in patients with allergic asthma.

Key Dates

Start date
Jun 19, 2024
Status verified
May 2025
Primary completion
Oct 31, 2025
Completion
Oct 31, 2025

Study Design

Enrollment
69 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: JYB1904: Dose-1
  • Experimental: JYB1904: Dose-2
  • Experimental: JYB1904: Dose-3
  • Active Comparator: Omalizumab

Primary Outcome Measure

Serum concentrations of JYB1904 [ Time Frame: Baseline through 337 days post-dose ]

Related Studies